Research programme: adeno-associated virus gene therapy - Kings College London/PfizerAlternative Names: AAV gene therapy - Kings College London/Pfizer
Latest Information Update: 19 Oct 2016
At a glance
- Originator Kings College London
- Developer Kings College London; Pfizer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inborn genetic disorders